Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label adjuvant Pegasys study in high-risk primary cutaneous melanoma
2006-000853-23Phase 3Completed
- Sponsor
- Kožní ordinace
- Start
- Jun 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa in cutaneous melanoma (CM) (2 arms), sponsored by Kožní ordinace. Primary endpoint: Distant relapse within 5 years. Started Jun 2006; status: completed.
02
Drugs
interferon alfa
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2006-000853-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000853-23.